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Exploring the IL-21–STAT3 Axis as Therapeutic Target
for Se´zary Syndrome
Leslie van der Fits1, Jacoba J. Out-Luiting1, Cornelis P. Tensen1, Willem H. Zoutman1
and Maarten H. Vermeer1
Se´zary syndrome is an aggressive cutaneous T-cell lymphoma. The malignant cells (Se´zary cells) are present in
skin, lymph nodes, and blood, and express constitutively activated signal transducer and activator of transcription
(STAT)3. STAT3 can be activated by IL-21 in vitro and the IL-21 gene itself is a STAT3 target gene, thereby creating an
autocrine positive feedback loop that might serve as a therapeutic target. Se´zary cells underwent apoptosis
when incubated with Stattic, a selective STAT3 inhibitor. STAT3 activation in Se´zary cells did not affect expression
of the supposed anti-apoptotic STAT3 target genes BCL2, BCL-xL, and SURVIVIN, whereas expression of
(proto)oncogenes miR-21, TWIST1, MYC, and PIM1 was significantly increased. CD3/CD28-mediated activation
of Se´zary cells induced IL-21 expression, accompanied by STAT3 activation and increased proliferation. Blocking
IL-21 in CD3/CD28-activated cells had no effects, whereas Stattic abrogated IL-21 expression and cell proliferation.
Thus, specific inhibition of STAT3 is highly efficient in the induction of apoptosis of Se´zary cells, likely mediated
via the regulation of (proto)oncogenes. In contrast, blocking IL-21 alone seems insufficient to affect
STAT3 activation, cell proliferation, or apoptosis. These data provide further insights into the pathogenic role
of STAT3 in Se´zary syndrome and strengthen the notion that STAT3 represents a promising therapeutic target in
this disease.
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INTRODUCTION
Signal transducer and activator of transcription (STAT)3
is a transcription factor that has a critical role in various
fundamental cellular processes such as cell development,
growth, and homeostasis. Under physiological conditions,
STAT3 can be activated by various growth factors or cyto-
kines, mediated by receptor-associated JAK kinases, as well
as by non-receptor Tyr kinases (Yu et al., 2007). Upon activa-
tion, STAT3 is phosphorylated on the Tyr residue at position
705, followed by dimerization via reciprocal phosphoTyr-SH2
interactions, translocation into the nucleus, and binding to
the DNA-binding motifs in the promoter regions of the
target genes.
STAT3 was found to be activated inappropriately in a wide
variety of human cancers. STAT3 acts as a central mediator of
neoplastic cellular transformation (Yu and Jove, 2004; Frank,
2007), and, in certain cellular contexts, its continuous
activation is sufficient for oncogenesis (Bromberg et al.,
1999). Target genes of STAT3 are involved in various stages
of tumor development including proliferation, survival, self-
renewal, invasion, and angiogenesis (Yu and Jove, 2004;
Frank, 2007). Together, this implies STAT3 as a key player
in the oncogenic process, and consequently as a target for the
molecular therapy of cancer. Indeed, inhibition of STAT3 by
different means can exert anti-cancer effects, mainly by the
induction of apoptosis of tumor cells (Frank, 2007).
Se´zary syndrome (SS) is a leukemic variant of cutaneous
T-cell lymphoma. Malignant cells (SS cells) are CD4þ T cells
with a skin-homing memory phenotype, and can be found in
patients’ skin, blood, and lymph nodes. SS cells show
constitutive phosphorylation STAT3 at position Tyr705
(Zhang et al., 1996; Nielsen et al., 1999; Eriksen et al.,
2001; van Kester et al., 2008). Inhibition of STAT3
phosphorylation using inhibitors of upstream JAK kinases
results in apoptosis of SS cells (Eriksen et al., 2001; van
Kester et al., 2008). We recently showed that STAT3 can be
activated in SS cells by IL-21 (van der Fits et al., 2012). IL-21 is
a cytokine belonging to the common-g chain family of
cytokines. It is produced by different subsets of activated
CD4þ T cells and NK-T cells, and has complex activities on
various cell types, including enhancement of adaptive T-cell
immunity, antibody production, activation and maturation of
NK cells, and impairment of regulatory T-cell development
and function (Davis et al., 2007). The IL-21 receptor is
comprised of two chains, the common-g chain and an
IL-21-specific receptor chain (IL-21R). IL-21R expression can
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be found on a variety of immune cells, as well as on
nonimmune cells such as endothelial and epithelial cells
(Monteleone et al., 2008, 2009). We previously demon-
strated increased expression of IL-21R on Se´zary cells when
compared with CD4þ cells from healthy donors (van der Fits
et al., 2012). As IL-21 is a direct STAT3 target gene in healthy
T cells (Caprioli et al., 2008), as well as SS cells (van der Fits
et al., 2012), an autocrine positive feedback loop can be
involved in the activation of STAT3 and in the subsequent
resistance to apoptosis in SS cells.
In this study, we investigated the feasibility of therapeutic
targeting of the IL-21—STAT3 autocrine loop in SS. We show
that selective blocking of IL-21 does not affect apoptosis
or cell proliferation. In contrast, inhibition of STAT3 using
Stattic induces apoptosis and simultaneously attenuates cell
proliferation.
RESULTS
Stattic causes rapid apoptosis of SS cells
Treatment of SS cells with AG490 or Cucurbitacin I (JSI-124)
results in decreased STAT3 phosphorylation, accompanied by
induction of apoptosis (Eriksen et al., 2001; van Kester et al.,
2008). As both compounds do not specifically target STAT3
but rather function as inhibitors of upstream JAK kinases, we
investigated the effects of treatment of SS cells with Stattic, a
compound specifically targeting the SH2 domain of STAT3,
thereby preventing STAT3 dimerization, activation, and
nuclear translocation (Schust et al., 2006).
Stattic causes a dose-dependent inhibition of the viability of
SS cells, demonstrated for primary cells as well as the Se´zary cell
lines SeAx en HuT-78. Both primary cells and cell lines show a
comparable sensitivity toward Stattic (Figure 1a). This decreased
viability was caused by the induction of apoptosis, as revealed
by the detection of active caspase-3 as early as 6hours after
addition of Stattic (Figure 1b). In addition, flow cytometric
analysis for propidium iodide and AnnexinV revealed a decrease
in the percentage of viable cells, whereas the percentage of
apoptotic and dead cells was increased (Figure 1c). Similar
effects of Stattic were observed for CD4þ cells from healthy
donors. However, the level of induction of apoptosis seems less
in healthy CD4þ cells than in SS cells (Figure 1c).
IL-21 induces (proto)oncogenes rather than anti-apoptotic genes
Many STAT3 target genes regulate cellular processes impor-
tant in oncogenesis (reviewed in the study by Frank, 2007). In
this study, we examined a number of previously described
STAT3 target genes involved in regulation of proliferation and
apoptosis. Primary SS cells were treated for various time points
with IL-21 to activate STAT3, and expression of putative
STAT3 targets was assayed by quantitative RT-PCR. In line
with previous studies (van der Fits et al., 2011), the oncogenic
pri-miR-21 was significantly induced in SS cells, thereby
serving as a positive control (Figure 2a). Interestingly, expres-
sion of anti-apoptotic genes BCL2, BCL-xL, and SURVIVIN
was not induced by IL-21, whereas only marginal induction
was observed for MCL1. In contrast, (proto)oncogenes
TWIST1, PIM1, and MYC were strongly induced by IL-21
(Figure 2a).
Blocking IL-21 does not influence SS cell survival
We previously demonstrated that IL-21 is a potent inducer of
STAT3 in SS cells (van der Fits et al., 2012). To investigate
whether IL-21 and the IL-21 receptor (IL-21R) can serve as
therapeutic targets, we assayed the effect of blocking IL-21
using IL-21R-Fc chimera protein. The efficacy of this protein in
Se´zary cells was experimentally validated in dose-response
and time course experiments (data not shown). Incubation of
primary SS cells with IL-21R-Fc chimera for 72 hours did not
consistently affect cell numbers (data not shown, n¼ 4) or cell
cycle progression (data not shown, n¼4). In addition,
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Figure 1. Specific inhibition of signal transducer and activator of
transcription (STAT)3 by Stattic results in apoptosis of Se´zary cells. (a) Primary
Se´zary syndrome (SS) cells (n¼ 2), SeAx or HuT-78 cells were cultured with
Stattic or DMSO. After 72 hours, cell viability was assayed using the WST test,
and calculated relative to cells cultured in medium. NA, not assayed.
(b) Primary SS cells were cultured for 6 hours with 10mM Stattic or the
volume equivalent DMSO, centrifuged onto glass slides, and stained for
active caspase-3. A representative example of four patients is shown.
(c) CD4þ cells from healthy donors or Se´zary patients were cultured for
24 hours with 10mM Stattic, or the volume equivalent of DMSO. Apoptosis
was assayed by flow cytometry. Alive cells were defined as being double
negative for AnnexinV and propidium iodide (PI). Apoptotic cells were
AnnexinVþ and PI , whereas dead cells were AnnexinVþ and PIþ .
The mean % of cells ± SEM is shown for n¼ 3 (healthy controls, HC)
or n¼ 4 (Se´zary patients, SS).
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blocking IL-21 did not result in apoptosis, whereas STAT3
inhibition by Stattic strongly induced apoptosis of SS cells
(Figure 2b).
CD3/CD28 stimulation of SS cells induces IL-21 expression
and STAT3 activation, which is unaffected by blocking autocrine
IL-21 signaling
The lack of effect of blocking IL-21 on survival of SS cells
might be due to the relative inert state of SS cells cultured
in vitro. To bypass this, we assayed the effect of blocking
IL-21 in SS cells simultaneously activated by CD3/CD28-
coated beads.
Stimulation of CD4þ cells from healthy donors and SS
patients with CD3/CD28-coated beads resulted in secretion of
IL-21 protein in the culture supernatant (Figure 3a), whereas
IL-21 was hardly detectable when cells were left unstimulated
(data not shown). Interestingly, IL-21 secretion by SS cells
was increased compared with cells from healthy donors
when stimulated overnight, whereas this difference was not
observed anymore when cells were stimulated for 3 days
(Figure 3a). For SS cells, we additionally showed that this
induction of IL-21 protein secretion was accompanied by
increased mRNA expression (Figure 3b).
Addition of IL-21R-Fc chimera to the culture medium did
not result in attenuation of IL-21 RNA and intracellular IL-21
expression (Figures 3b and d), but significantly reduced the
level of IL-21 protein in the culture medium (Figure 3c),
demonstrating that the secreted IL-21 is efficiently captured by
the IL-21R-Fc chimera. The CD3/CD28-induced IL-21 expres-
sion was accompanied by elevated activation of STAT3,
which was not affected by addition of the IL-21-blocking
protein (Figure 3e). In addition, blocking autocrine IL-21 in
CD3/CD28-activated SS cells did not exert any effect on the
expression of STAT3 target genes pri-miR-21, TWIST1, PIM1,
and MYC (data not shown). In contrast, selective targeting of
STAT3 in CD3/CD28-activated SS cells using Stattic resulted
in decreased IL-21 expression, STAT3 activation (Figure 3),
and expression of STAT3 target genes (data not shown).
Summarized, CD3/CD28 activation of Se´zary cells results in
increased IL-21 production and activation of STAT3. Inhibition
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Figure 2. IL-21 induces expression of (proto)oncogenes rather than anti-apoptotic genes, and blocking IL-21 does not affect apoptosis. Primary Se´zary
syndrome (SS) cells were stimulated with IL-21 for 1, 2, 4, and 8 hours and RNA was extracted. mRNA expression of the genes indicated was determined by
quantitative reverse transcriptase in real-time PCR (QPCR), and calculated relative to expression in non-stimulated cells. As induction of the different genes
in each patient did not occur with identical kinetics, we determined the maximum fold induction for each gene and patient. For each gene, the mean
of this maximum fold is depicted ± SEM for n¼6 patients. Asterisks indicate significant differences (Wilcoxon rank test, Po0.05) (a). Primary SS cells were
incubated with 10mg ml 1 of IL-21R-Fc chimera (anti-IL-21) or 10mM Stattic for 72 hours, and apoptosis was assayed by flow cytometry for AnnexinV and
propidium iodide (PI). The experiment shown is representative of n¼ 2 (b).
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of autocrine IL-21 feedback signaling does not effectively
downregulate STAT3 activation and expression of STAT3
target genes. Similar results were obtained using SS cells
mitogenically stimulated by PMA/ionomycin or PHA (data
not shown).
Blocking IL-21 does not affect CD3/CD28-induced proliferation,
whereas blocking STAT3 does
Polyclonal stimulation of SS cells by CD3/CD28 beads
resulted in the formation of clusters of cells, indicative for
cell proliferation and/or activation. This was not affected by
addition of IL-21R-Fc chimera, whereas cluster formation was
prevented by Stattic (Figure 4a). This observed cell activation
was reflected in the cell numbers obtained after culture
(Figure 4a). Cell proliferation analysis revealed that SS cells
cultured in medium alone were inactive and not proliferating,
i.e., in G1 phase (Figure 4b). Upon culturing with CD3/CD28-
coated beads, cells in G2 and S phase could be recognized.
Percentages of cells in G2 and/or S phase were not affected by
co-culture with IL-21-blocking protein, whereas the addition
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Figure 3. Polyclonal stimulation of Se´zary cells results in IL-21 production and signal transducer and activator of transcription (STAT)3 activation, which
is not influenced by anti-IL-21. CD4þ cells isolated from healthy controls (n¼3, HC) or Se´zary patients (n¼ 3 or 5, SS) were stimulated with CD3/CD28
beads for 1 or 3 days. IL-21 protein secretion in the culture supernatant was assayed by ELISA (a). Primary Se´zary cells (n¼5) were cultured for 3 days in medium,
medium with CD3/CD28 beads, or with CD3/CD28 beadsþ anti-IL-21, or with CD3/CD28 beads and Stattic. IL-21 expression was assayed on mRNA
level by quantitative reverse transcriptase in real-time PCR (QPCR) (b) or on protein level by ELISA (c). In addition, intracellular IL-21 was detected by flow
cytometry. Cells were stained for expression of CD3 and IL-21. The experiment shown is representative for n¼2 (d). pSTAT3 expression was assayed by flow
cytometry, and the median fluorescent intensity (MFI) is indicated in the figure. The experiment shown is representative of n¼ 3 (e). NA, not assayed.
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of Stattic strongly prevented cell proliferation (Figure 4b).
Stimulating SS cells with mitogenic stimuli as PMA/ionomycin
or PHA instead of CD3/CD28 yielded in similar results (data
not shown). To exclude the possibility that the observed CD3/
CD28-induced proliferation was caused by admixed reactive
CD4þ cells, these cell cycle experiments were repeated using
SS cells that were nearly 100% pure, based on an aberrant
immunophenotype (i.e., loss of CD7 expression). This yielded
identical results, demonstrating that the observed CD3/CD28-
induced cell proliferation was within the malignant cell
population (data not shown).
In conclusion, polyclonal or mitogenic stimulation of SS
cells results in proliferation of cells, which is dependent on
STAT3 signaling but is independent of the secretion of IL-21.
DISCUSSION
We demonstrate here that blocking IL-21 does not affect
STAT3 activity, apoptosis, or proliferation of primary SS cells,
indicating that inhibition of IL-21 signaling is not sufficient to
interfere in these processes. In contrast, blocking STAT3 using
Stattic results in increased apoptosis and attenuation of cell
proliferation, further substantiating the critical role for STAT3
in the oncogenic process in SS.
Our data show that STAT3 inhibition by Stattic can cause
apoptosis of SS cells cultured in vitro in the absence of
co-stimulation by CD3/CD28 (Figure 1), and in the absence
of detectable STAT3 phosphorylation (Figure 3e). Similar
observations were made very recently in colorectal cancer
cell lines in which treatment with Stattic resulted in significant
increased sensitivity toward chemoradiotherapy while phos-
phorylated STAT3 was not detectable. Off-target effects of
Stattic in these experiments were excluded by demonstrating
identical effects of shRNA-mediated silencing of STAT3
(Spitzner et al., 2014). These puzzling observations in our
and this recently published study might be explained by
technical issues, for e.g., by the inability to detect low levels
of phosphorylated STAT3 that can still have a physiological
role. In addition, the effects of Stattic on unphosphorylated
STAT3 can serve as an alternative explanation for the observed
results. Stattic selectively inhibits the SH2 domain of STAT3,
irrespective of its phosphorylation status (Schust et al., 2006).
It has become increasingly clear that unphosphorylated STAT3
can also drive gene expression, among others, of well-known
oncogenes, and has been implicated in oncogenesis (Yang
et al., 2005; Yang and Stark, 2008).
Stimulation of SS cells by IL-21 results in STAT3 activation,
coinciding with increased expression of (proto)oncogenes
miR-21, TWIST1, PIM1, and MYC. This nicely correlates with
the previously reported overexpression of miR-21 (van der Fits
et al., 2011), TWIST1 (van Doorn et al., 2004), and MYC
(Vermeer et al., 2008) in SS, and indicates that these genes are
downstream STAT3 target genes mediating the oncogenic
effects of STAT3. STAT3 binding to its target genes is cell
type– and context-dependent, as illustrated by the limited
overlap between data sets of genome-wide studies on different
cell types (Chen et al., 2008; Kwon et al., 2009; Hutchins
et al., 2012). Studies on selected candidate genes identified
several bona fide STAT3 target genes mediating the oncogenic
function of STAT3 in various tumor types. miR-21 was
previously shown to be directly regulated by STAT3 and
pathologically involved in multiple myeloma (Loffler et al.,
2007). In addition, expression of the transcription factor
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Figure 4. Polyclonal stimulation of Se´zary cells causes cell proliferation, which is unaffected by anti-IL-21, but reduced by Stattic. Primary Se´zary syndrome
(SS) cells were cultured for 3 days with the stimuli indicated. Cells were photographed and counted. Relative cell numbers ± SEM are indicated (a, n¼ 4).
(b) Cellular DNA of the cultured SS cells was stained by propidium iodide (PI), and the cell cycle status was assayed by flow cytometry. The peaks with
different DNA content represent cells in G1 and G2 phase. The example shown is representative of n¼ 5.
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TWIST1 is under direct control of STAT3 in breast cancer cells
and is involved in mediating (part of the) oncogenic function
of STAT3 (Cheng et al., 2008). We observed that treatment of
SS cells with IL-21 results in STAT3 activation, accompanied
with increased expression of TWIST1 and miR-21, thereby
indicating that these genes are candidate STAT3 target genes
in SS as well. Previous gene expression analysis of Se´zary cells
treated with IL-21 for 4 hours identified a very limited set of
upregulated genes, including PIM1 (Marzec et al., 2008),
which was confirmed in our study. Other putative STAT3
target genes identified in our study (i.e., miR-21, TWIST1, and
MYC) were not identified by Marzec, probably as a
consequence of the transient nature of the induction of these
genes.
Blocking IL-21 in Hodgkin lymphoma cell lines results in
reduction of STAT3 activity and expression of STAT3 target
genes (Lamprecht et al., 2008). Also, in ALK-positive
anaplastic large-cell lymphoma cell lines, STAT3 activity
was efficiently blocked by targeting IL-21 or IL-21R (Dien
Bard et al., 2009). In contrast, we demonstrate that blocking
the autocrine IL-21 loop in SS cells did not have a significant
effect on STAT3 activation or on expression of its target genes,
although efficient downregulation of IL-21 secretion in the
medium was confirmed. STAT3 can be activated by multiple
cytokines and growth factors (Murray, 2007; Yu et al., 2007),
including cytokines that are (over)expressed in SS, such as the
anti-inflammatory IL-10 (Dummer et al., 1996). In addition, IL-
31, whose overexpression in SS was demonstrated recently
(Ohmatsu et al., 2012), is capable of inducing, among others,
phosphorylation of STAT3 (Cornelissen et al., 2012). It is clear
that further research should be conducted to elucidate
whether the constitutive STAT3 activity in SS in vivo can be
attributed to a single cytokine or growth factor, or whether this
is a result of a combination of factors.
IL-21 can have tumor-promoting effects on IL-21R-positive
malignant lymphocytes. Hodgkin lymphoma cell lines are
protected from apoptosis by IL-21 (Dien Bard et al., 2009),
and IL-21 induces proliferation of human myeloma cells,
while inhibiting apoptosis (Brenne et al., 2002). In ALK-
positive anaplastic large-cell lymphoma, cell survival was
significantly enhanced by IL-21, whereas this was reduced
by inhibiting IL-21R (Dien Bard et al., 2009). IL-21 did not
induce proliferation of SS cells, but ameliorated apoptosis
(Marzec et al., 2008; Yoon et al., 2008). Our study shows that
blocking IL-21 does not affect survival, proliferation, or
apoptosis of primary SS cells, both in resting and activated
cells, under the experimental conditions used. The polyclonal
and mitogenic stimulation of cells might induce a plethora of
activator pathways, which cannot be inhibited by blocking a
single cytokine.
In conclusion, although our results do not support a critical
role for IL-21/IL-21R signaling in survival of Se´zary cells,
targeting STAT3 in SS still seems an attractive therapeutic
option. STAT3 inhibition using the selective inhibitor Stattic
results in SS cell apoptosis and inhibition of cell proliferation.
As constitutive STAT3 activation is observed in a wide variety
of solid and hematological tumors, much research effort
is put into developing STAT3-blocking strategies (reviewed
in the study by Masciocchi et al., 2011). Several direct
inhibitors of STAT3 have entered clinical trials, such as the
synthetic compounds OPB-33121 and OPB-51602, as
well as the STAT3 decoy and antisense oligonucleotides
(www.clinicaltrials.gov). In addition, it is becoming clear
that numerous anti-cancer compounds originally developed
to target other pathways, or for which the underlying anti-
tumor mechanisms are not completely understood, can cause
a reduction of STAT3 activity, thereby putatively contributing
to the beneficial effect. (for e.g., Zhang et al., 2008; Tiffon
et al., 2011; Gupta et al., 2012).
MATERIALS AND METHODS
Patient selection and cell isolation
Eleven patients (8 females, 3 males; median age 65 years, range
47–82 years) were diagnosed with SS on the basis of the criteria of the
WHO/EORTC classification (Willemze et al., 2005; Olsen et al.,
2007). Patient characteristics are shown in Table 1. In addition, blood
was drawn from three healthy donors. CD4þ cells were purified as
previously described (van der Fits et al., 2011). Approval for these
studies was obtained from the Leiden University Medical Center
review board, and written informed consent was provided according
to the Declaration of Helsinki Principles.
Cell culturing and stimulation experiments
The Se´zary cell lines HuT-78 (ATCC number TIB-161), SeAx (kindly
provided by Dr K Kaltoft) (Kaltoft et al., 1987), and primary CD4þ
cells were cultured as described previously (van der Fits et al., 2011).
For the identification of STAT3 targets in Se´zary cells, cells were
cultured overnight in a cytokine-deprived medium, and subsequently
stimulated with 100 ng ml 1 of IL-21 (ImmunoTools, Friesoythe,
Germany) for 1, 2, 4, or 8 hours. Polyclonal stimulation of Se´zary
cells was achieved using CD3/CD28 beads (Dynabeads Human
T-activator CD3/CD28, Invitrogen Dynal AS, Oslo, Norway) at a ratio
of 1:5 (beads:cells). Stattic (Calbiochem, San Diego, CA) was dissolved
in DMSO (100 mM), and used at a final concentration of 10mM, or
indicated otherwise. Blocking exogenous IL-21 was achieved using
recombinant IL-21R-Fc chimera (R&D systems, Minneapolis, MN) at a
concentration of 10mg ml 1.
Flow cytometry
STAT3 activation was assayed using antibodies directed against
phosphorylated STAT3 (BD Biosciences, Franklin Lakes, NJ) as
described previously (van der Fits et al., 2011).
Flow cytometric detection of apoptosis was performed by staining
cells with allophycocyanin-conjugated antibodies against AnnexinV
and propidium iodide using the apoptosis detection kit (eBioscience,
San Diego, CA).
To assay the cell cycle, cells were fixed in 2% paraformaldehyde
for 15 minutes at room temperature, followed by cold 70% ethanol
for 15 minutes at 4 1C. RNA was digested by 100mg ml 1 RNase A
(Qiagen, Hilden, Germany), and DNA was stained using propidium
iodide (eBioscience).
For detection of intracellular IL-21, cells were stimulated for 1 hour
with the stimuli indicated, before incubation with 10mg ml 1 Brefel-
din A (Sigma, Zwijndrecht, The Netherlands) for another 5 hours. Cells
were fixed in 2% paraformaldehyde, followed by staining with
allophycocyanin-conjugated CD3 antibodies (BD Pharmingen, Breda,
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The Netherlands). Hereafter, cells were permeabilized in phosphate-
buffered saline with 0.2% BSA and 0.5% saponine (Sigma). Intracel-
lular staining was performed using PE-conjugated antibodies against
IL-21 (eBioscience), or an isotype control (BD Pharmingen).
Samples were acquired on a flow cytometer (FacsCalibur, BD
Biosciences), and the data were analyzed using FlowJo software
(Tree Star, Ashland, OR).
Quantitative PCR
mRNA expression levels of various genes were assayed in total RNA
isolated from cultured Se´zary cells using the RNeasy Mini kit
(Qiagen). RNA was treated with DNase I (Promega, Madison, WI)
and converted into cDNA by IScript reverse transcriptase (Bio-Rad,
Hemel Hempstead, UK), oligo(dT)12-18 and random hexamer primers
(Bio-Rad).
Table 1. Patient characteristics
Patient number Sex Age Treatment CD4/CD8 ratio Total lymphocyte count (109 l 1)
1a F 71 Prednisone 10 mg 162 18.5
1b F 72 Prednisone 10 mg
Chlorambucil 2 mg
105 20.0
2 F 82 Prednisone 20 mg
Radiotherapy
14 0.3
3 F 65 Prednisone 10 mg 18 2.3
4 F 64 Prednisone 10 mg 17 5.4
5 M 63 None 19 3.3
6 F 63 Prednisone 20 mg
Chlorambucil 2 mg
130 4.5
7 M 47 None 23 8.6
8 M 47 None 15 1.1
9 F 47 Prednisone 20 mg 35 6.4
10 F 79 None 34 4.9
11a F 69 Prednisone 5 mg
Chlorambucil 2 mg
81 5.0
11b F 73 Prednisone 20 mg
Chlorambucil 2 mg
98 3.2
11c F 74 Prednisone 10 mg
Chlorambucil 2 mg
152 8.3
12 M 81 Prednisone 10 mg
Chlorambucil 2 mg
203 35.0
Table 2. Sequences of the primers used for quantitative reverse transcriptase in real-time PCR
Gene FW primer REV primer Reference
Pri-miR-21 50-CATTGTGGGTTTTGAAAAGGTTA-30 50-CCACGACTAGAGGCTGACTTAGA-30 (Loffler et al., 2007)
TWIST1 50-CACTGAAAGGAAAGGCATCA-30 50-GGCCAGTTTGATCCCAGTAT-30 This study
PIM1 50-GTCCAAAATCAACTCGCTTGC-30 50-GAAACCCGAGCTCACCTTCTT-30 This study
JUN 50-TGACTGCAAAGATGGAAACG-30 50-CAGGGTCATGCTCTGTTTCA-30 This study
MYC 50-GGTGCTCCATGAGGAGACAC-30 50-CAGCAGAAGGTGATCCAGACTC-30 This study
BCL2 50-GCCCTGTGGATGACTGAGTA-30 50-GGCCGTACAGTTCCACAAAG-30 This study
BCL-xL 50-CTTGGATGGCCACTTACCTG-30 50-CTGCTGCATTGTTCCCATAG-30 This study
SURVIVIN 50-GTTGCGCTTTCCTTTCTGTC-30 50-TGGTTTCCTTTGCAATTTTGT-30 This study
MCL1 50-TCCCCTGCCATCCCTGAACTC-30 50-CGTGAAAGATGAAAGGTCTGTGGAC-30 This study
IL-21 50-CCTGGCAACATGGAGAGGATTG-30 50-TGTGGCGATCTTGACCTTGGG-30 (van der Fits et al., 2012)
ARF5 50-TGCTGATGAACTCCAGAAGATGC-30 50-CGGCTGCGTAAGTGCTGTAG-30 (van Kester et al., 2012)
ERCC3 50-ATATCCAAGGTAGGTGACACTTCG-30 50-TTGTACTCTTCTGCAACCATCCC-30 (van Kester et al., 2012)
TMEM87A 50-CATCTGGACAACCATGAAGTTCAG-30 50-AGGATCATGGAGAACAGCAAGC-30 (van Kester et al., 2012)
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Real-time PCR was performed in a 384-well format on a CFX384
PCR detection system (Bio-Rad), using iQ SYBR Green Supermix (Bio-
Rad), and the following cycle parameters: 5 minutes at 95 1C,
followed by 45 cycles of 15 seconds at 95 1C, 20 seconds at 60 1C,
and 20 seconds at 72 1C. Specificity of the PCR products was
confirmed by melting curve analysis. Primer sequences are listed in
Table 2. Data were analyzed using CFX Manager software (Bio-Rad)
applying the DDCt method. Expression was normalized to the stably
expressed reference genes ARF5, ERCC3, and TMEM87A (van Kester
et al., 2012).
Immunocytochemistry
SS cells were cultured for 6 hours with 10mM Stattic or a
volume equivalent of DMSO. Cytocentrifuge preparations of these
cells were prepared using a Shandon CytoSpin III cytocentrifuge
(Thermo Scientific, Breda, The Netherlands). Cells were fixed in
acetone, blocked with 5% normal goat serum, and subsequently
incubated with a polyclonal rabbit antibody against the active
form of caspase-3 (BD Biosciences). Biotinylated goat-anti-rabbit
IgG (Vector Laboratories, Burlingame, CA) was used as secondary
antibody, followed by streptavidin–biotin–peroxidase complex
(DAKO, Glostrup, Denmark). Immunoreactivity was detected using
3-amino-9-ethylcarbazole, and slides were counterstained with
hematoxylin.
IL-21 ELISA
Culture supernatants were analyzed for IL-21 protein expression using
a commercially available ELISA kit (eBioscience) according to the
instructions provided by the manufacturer. Detection limit of the
ELISA was generally 150 pg ml 1.
Analysis of cell survival
To measure cell survival, primary SS cells were incubated with
Stattic in the concentrations indicated in a 96-well plate (six wells
per condition). After 72 hours, cell proliferation reagent WST-1
(Roche, Mannheim, Germany) was added, and absorbance at 450
and 650 nm (reference wavelength) was measured after 8 hours.
The number of viable cells was calculated relative to the numbers
of non-treated cells.
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